Lecture 3 - Cell communication II - tyrosine kinase-associated signalling pathways Flashcards

1
Q

What can cross the plasma membrane and interact with intracellular receptors?

A

Small hydrophobic molecules - such as steroid hormones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Can large hydrophilic signalling molecules - such as proteins- cross the plasma membrane?

A

no, they ineract with extracellular portion of transmembrane receptors. Molecules can cross plasma membrane via gated membrane channels (e.g. Ca2+ ions)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the properties of a hydrophilic extracellular domain that interacts with a ligand

A

often contains CONSERVED ELEMENTS:
- immunoglobin (Ig)-like domains
- epidermal growth factor (EGF)- like domains
- fibronectin type III repeats
- cysteine-rich regions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the properties of the transmembrane segment

A

usually 20-25aa of alpha-helical structure made up of hydrophobic amino acids which stabilised via interactions with fatty acid chains of the lipid bilayer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe hydrophilic signalling machinery

A

In the case of receptor tyrosine kinases (RTKs), this involves a tyrosine kinase domain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How is a protein inserted through the plasma membrane?

A

Genes encoding transmembrane proteins contain a single-peptide which directs the newly synthesized protein to the endoplasmic reticulum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is information transmitted from extracellular ligand to intracellular ‘effector’?

A
  • Conformational changes to multi-pass transmembrane receptors which are then often associated with G-proteins
  • The dimerisation/multimerisation of single pass transmembrane receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are transmembrane receptors important for?

A

Family of 58 single pass transmembrane receptors that include a tyrosine kinase domain. They are important for developmental/homeostatic roles.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain enzyme-coupled receptors

A

Dimerisation of extracellular ligand (e.g. platelet-derived growth factor). Each ligand bind to a receptor, which are then bought together and activate each other.

Other mechanisms include monomeric ligand with 2 ligand receptor binding sites. Binding of a ligand alters their affinity for one another (e.g. Epidermal growth factor - EGF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Do receptor tyrosine kinase have enzymatic activity?

A

Yes - receptors are bought together and phosphorylate/activate each other

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How many ommatidia per eye?

A

800 ommatidia per eye
- 8 photoreceptors
- 4 cone cells
- 2 primary pigment cells
- 6 secondary pigment cells
- 3 tertiary pigment cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the development of photoreceptors

A
  • imaginal discs are developing adult structures within the Drosophila larva
  • Differentiation of photoreceptors in the eye disc occurs over the course of 3rd install larval development
    -First photoreceptor cell, the R8, differentiates within the morphogenetic furrow
  • Rows added approximately every 2 hours with progressive recruitment of photoreceptors from the surrounding pool of undifferentiated cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What signaling pathway is required in R-cell recruitment?

A

EGFR-RAS/RAF-MEK-ERK signaling pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the EGFR-RAS/RAF-MEK-ERK pathway

A
  1. Dimerised PDGF (platelet-derived growth factor) ligands have a high affinity for receptors
  2. Receptors brought together due to ligand binding, leads to phosphorylation of p-Y residues in the cytosolic tail by intrinsic kinase domain of the opposite receptor.
  3. p-Y residues act as docking sites for the SH2 domain of adaptor protein Grb2
  4. SH3 domains of Grb2 bind proline-rich regions of Sos - a GDP to GTP exchange factor (GEF)
  5. Sos GEF activity swaps GDP to GTP in membrane associated Ras molecule activating it.
  6. Active ras-GTP binds to inhibitory domain of Raf
  7. Raf is a serine/threonine kinase that then activates itself
  8. Downstream pathway components MEK and Erk are activated in sequence and are all S/T kinases
  9. pErk translocates to the nucleus, interacts with Tis and triggers gene expression.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is R-cell recruitment regulated?

A
  1. Raf is negatively regulated by its own N-terminal region, the 14-3-3 protein and its own phosphorylation - all which need to be removed before the protein can be activated
  2. Erk contributes to multiple levels of negative regulation including including the ‘negative phosphorylation’ of Sos to prevent its binding to Grb2
  3. The activated PDGFR also recruits multiple negative regulators of the pathway including the RasGAP, phosphates and triggering endocytic internalisation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the roles of related small GTPases e.g. Rho family?

A

They are distinct from the trimeric G-proteins associated with GPCRs. However, they are membrane tethered, they are activated by being bound to the GTP nucleotide and they are regulated by GEFs (guanone nucleotide exchange factors) and GAPs (GTPase-activating proteins).

17
Q

What disease is associated with aberrant RTK signalling?

A
  • Ras/Raf/MEK/ERK signaling is activated in 80% of cutaneous melanomas
  • Activating mutations in the Ras/Raf/MAPK pathway represent the most common drivers of melanoma.
  • most mutations are within the kinase activation loop. Mutation of V600 resulting in constitutively active molecule with increased kinase activity.
18
Q

Describe how to stop disease associated with aberrant RTK signalling

A

Inhibitors of BRAF kinase activity have been developed to treat malignant melanoma. Early inhibitors associated with spectacular initial results followed by distressingly rapid development of resistance, disease relapse and progression.

More recent BRAF inhibitors have selected for mutant BRAF and reduced off-target effects (e.g. Vemurafenib & Dabrafenib). Patients often treated with both BRAF & MEK inhibitors (such as trametinib) to reduce development off resistance and improve outcomes. Immuno-therapies now also widely used.

19
Q

Describe features regarding pathways associated with cytokine receptors that signal via the JAK/STAT pathway

A
  • T cell receptors that bind to MHC (major histocompatibility complex)/antigens being presented to them and ultimately signal to the nucleus
  • Integrins are responsible for intercellular adhesion and focal adhesions
  • all have receptor-associated tyrosine kinases
20
Q

Describe the parts of the JAK/STAT pathway

A
  • 4 Janus Kinases (JAK1, JAK2, JAK3, TYK2)
  • 7x signal transducer and activator of transcription (STAT1-4, STAT5a, STAT5b & STAT6)
  • Multiple layers of feedback and negative regulation (SOCS, PTP, PIAS)
21
Q

Describe the pathway of JAK2

A

Tpo –> MPL –> JAK2 –> STAT3/5a/5b –> target genes

Epo –> EPO-R –> JAK2 –> STAT3/5a/5b –> target genes

Target genes that promote both stem cell renewal/proliferation and differentiation into megakaryocytic and erythroid progenitors

22
Q

What disease all feature JAK/STAT pathway activation?

A

Myeloproliferative neoplasms - most common mutation is JAK2 - there shoukd be 1% specific activity, however at 8% it is considered disease.

23
Q

What are Type II inhibitors?

A

bind and stabilize inactive conformation of the kinase with the flipped aspartate residue facing outward of the binding pocket

23
Q

What are Type I inhibitors?

A

bind to the active conformation of the kinase with the aspartate residue (white backbone) of the DFG motif pointing into the ATP-binding pocket

24
Q

How many types of inhibitors are there?

A

4

25
Q

What are Type IV inhibitors?

A

Bind to an allosteric pocket remote from the ATP-binding pocket

25
Q

What are Type III inhibitors?

A

occupy an allosteric pocket that is adjacent to the ATP-binding pocket but doesn’t overlap with it.